Company profile: aTyr Pharma
1.1 - Company Overview
Company description
- Provider of biotherapeutics discovering and developing protein biologics, including efzofitimod, an immunomodulator targeting interstitial lung disease (pulmonary sarcoidosis and systemic sclerosis-related ILD); a tRNA synthetase biology platform; ATYR0101 targeting fibrosis via LTBP1; ongoing and completed efzofitimod clinical trials; and Pangu BioPharma developing bispecific antibodies for diseases like cancer.
Products and services
- Efzofitimod: Clinical-stage biologic immunomodulator targeting interstitial lung disease, with specific application in pulmonary sarcoidosis and systemic sclerosis-related ILD
- Ongoing Clinical Trials for Efzofitimod: Ongoing clinical investigations assessing efzofitimod’s efficacy and safety in ILD patients, specifically those with pulmonary sarcoidosis and systemic sclerosis-related ILD
- TRNA Synthetase Biology Platform: Discovery platform leveraging tRNA synthetase biology to identify new therapeutic intervention points for fibrosis and inflammation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to aTyr Pharma
Aeglea BioTherapeutics
HQ: United States
Website
- Description: Provider of clinical-stage enzyme therapies for rare metabolic diseases and investigational monoclonal antibody programs for IBD, including SPY001 targeting α4β7 integrin and SPY002 targeting TL1A, with rational combination studies (SPY120, SPY130, SPY230) and precision immunology approaches using genetic or biomarker-based patient selection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aeglea BioTherapeutics company profile →
Som Pharmaceuticals
HQ: Switzerland
Website
- Description: Provider of novel anti-tumour somatostatin analogue (SSA) peptide medicines and diagnostics for patients with rare diseases that have unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Som Pharmaceuticals company profile →
ApcinteX
HQ: United Kingdom
Website
- Description: Provider of therapies that modulate the anticoagulant APC pathway to treat haemophilia, developing a drug that turns down this pathway to restore normal blood clotting, with potential applicability across all haemophilia types.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ApcinteX company profile →
Strongbridge Biopharma
HQ: Ireland
Website
- Description: Provider of therapies for rare endocrine disorders and related conditions, including Gvoke HypoPen (FDA-approved autoinjector for severe hypoglycemia in adults and children aged 2 years and above with diabetes), Keveyis (FDA-approved for Primary Periodic Paralysis), Recorlev (cortisol synthesis inhibitor for endogenous hypercortisolemia in adult Cushing’s), and Ogluo (glucagon injection approved in the UK/EU).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Strongbridge Biopharma company profile →
BioCryst
HQ: United States
Website
- Description: Provider of ORLADEYO (berotralstat), an oral plasma kallikrein inhibitor for prophylaxis to prevent hereditary angioedema attacks in adults and pediatric patients 12 years and older, and RAPIVAB (peramivir injection) for acute uncomplicated influenza; also developing BCX10013 (oral Factor D inhibitor) and an oral C5 inhibitor for complement-mediated diseases, BCX17725 for Netherton syndrome, and avoralstat for diabetic macular edema.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioCryst company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for aTyr Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to aTyr Pharma
2.2 - Growth funds investing in similar companies to aTyr Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for aTyr Pharma
4.2 - Public trading comparable groups for aTyr Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →